TY - JOUR
T1 - Dermatomyositis induced by drug therapy
T2 - A review of case reports
AU - Seidler, Anne M.
AU - Gottlieb, Alice B.
N1 - Funding Information:
Supported by a generous grant from Ms Joan Fabry.
PY - 2008/11
Y1 - 2008/11
N2 - Background: Drugs have occasionally been implicated in dermatomyositis (DM) onset. Objective: We sought to review case reports of drug-induced DM. Methods: Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined. Results: In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug. Limitations: Case reports may emphasize unusual findings. Conclusions: Further work is needed to differentiate drug effects from underlying, predisposing factors.
AB - Background: Drugs have occasionally been implicated in dermatomyositis (DM) onset. Objective: We sought to review case reports of drug-induced DM. Methods: Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined. Results: In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug. Limitations: Case reports may emphasize unusual findings. Conclusions: Further work is needed to differentiate drug effects from underlying, predisposing factors.
UR - http://www.scopus.com/inward/record.url?scp=53349141343&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2008.05.034
DO - 10.1016/j.jaad.2008.05.034
M3 - Review article
C2 - 18625537
AN - SCOPUS:53349141343
SN - 0190-9622
VL - 59
SP - 872
EP - 880
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 5
ER -